The Massachusetts Appeals Court has affirmed the dismissal of a woman’s claims that she was injured by knee-pain injections manufactured by biotech company Genzyme.

Patricia M. Dunn filed the suit in state court arguing that Genzyme’s product Synvisc-One is regulated as a Class III supplement by the Medical Device Amendments and subject to pre-market approval.